Table 1.
Demographical and clinical characteristics of participants.
| PD | ET-PD | Significance | |
|---|---|---|---|
| n | 53 | 30 | |
| Age (years) | 76.5 ± 3.4 | 77.5 ± 7.6 | p = 0.51a |
| Female gender | 24 (45.3) | 11 (36.7) | p = 0.45b |
| Non-Hispanic white | 48 (90.6) | 26 (86.7) | p = 0.72c |
| Education (years) | 16.5 ± 2.7 | 15.1 ± 4.4 | p = 0.12a |
| Disease duration (years) | 9.9 ± 12.5 (6.0) | 32.3 ± 22.1 (28.0) | p < 0.001d |
| CIRS score | 8.0 ± 3.4 | 8.4 ± 3.7 | p = 0.67a |
| CESD-10 score | 9.5 ± 5.3 | 9.1 ± 5.8 | p = 0.79a |
| Total tremor score | NA | 24.0 ± 5.3 | NA |
| Total number of prescription medications | 6.5 ± 2.9 | 6.3 ± 3.4 | p = 0.77a |
| Takes medication for ET | NA | 22 (73.3) | NA |
| Number of medications for ET | NA | 1.0 ±0.8 (0–3) | NA |
| Takes medication with GABA-ergic properties | 2 (3.8) | 8 (26.7) | p = 0.004c |
| Takes dopamine agonist | 9 (17.0) | 4 (13.3) | p = 0.76c |
| Takes amantadine | 3 (5.7) | 2 (6.7) | p = 1.00c |
| Takes selegiline | 13 (24.5) | 2 (6.7) | p = 0.04b |
| Takes anticholinergic agent | 0 (0.0) | 0 (0.0) | p = 1.00b |
| Takes carbidopa–levodopa | 45 (84.9) | 15 (50.0) | p = 0.001b |
| Carbidopa–levodopa dose (mg)e | 337.9 ± 342.1 (200) | 486.7 ± 274.8 (300) | p = 0.02d |
| Years on carbidopa–levodopae | 6.1 ± 4.3 | 5.9 ± 4.3 | p = 0.88d |
Values are mean ± SD (median or range) or number (percentage).
CESD-10, Center for Epidemiological Studies Depression Scale; CIRS, Cumulative Illness Rating Scale; ET, essential tremor; GABA, gamma aminobutyric acid; mg, milligrams; NA, not applicable; PD, Parkinson’s disease.
aStudent’s t-test.
bChi-squared test.
cFisher’s exact test.
dMann–Whitney test.
eAmong participants taking carbidopa–levodopa.
NA, not applicable.